Frontiers in Anti-Cancer Drug Discovery: Volume 9

 
 
Frontiers in Anti-Cancer Drug Discovery (Verlag)
  • 1. Auflage
  • |
  • erschienen am 6. Dezember 2018
  • |
  • 275 Seiten
 
E-Book | ePUB mit Adobe DRM | Systemvoraussetzungen
978-1-68108-701-6 (ISBN)
 

Frontiers in Anti-Cancer Drug Discovery is a book series devoted to publishing the latest advances in anti-cancer drug design and discovery. In each volume, eminent scientists contribute reviews relevant to all areas of rational drug design and drug disc

  • Englisch
  • Sharjah
  • |
  • Vereinigte Arabische Emirate
PublishDrive
  • 2,48 MB
978-1-68108-701-6 (9781681087016)
weitere Ausgaben werden ermittelt
  • Cover
  • Title
  • Biblography
  • End User License Agreement
  • Contents
  • Preface
  • List of Contributors
  • Recent Advances and New Insights for the Therapeutic Intervention of Cancer
  • Nhi Nguyen1, Stina George Fernandes2, Ekta Khattar2 and Yinghui Li1,*
  • TARGETING DNA DAMAGE RESPONSE (DDR) IN CANCER
  • DNA Damage Response Pathways
  • Base Excision Repair (BER)
  • DNA Mismatch Repair (MMR)
  • Nucleotide Excision Repair (NER)
  • DNA Double Strand Break Repair
  • DDR Associated Cell Signalling Pathways
  • DDR as an Anticancer Drug Target
  • DDR Inhibitors in Clinical Development
  • Combining DDR Inhibitors with DNA Damaging Radiotherapy and Chemotherapy
  • Future Prospects of DDR Targeting Agents in Cancer Treatment
  • Synthetic Lethality
  • DDR with Epigenetic Compounds
  • IMMUNOTHERAPY
  • Common Immunotherapeutic Approaches
  • Cytokine Therapy
  • Antibody Immunotherapy
  • Therapeutic Cancer Vaccination Therapy
  • Oncolytic Viruses Therapy
  • Adoptive Cell Transfer Therapy
  • The Basis Behind CAR-T and CD19 CAR-T Therapy
  • Advantages of CD19 CAR-T Cell Therapy
  • Common Side Effects and Considerations of CD19 CAR-T Cell Therapy
  • Clinical Application and Drug Development of CD19 CAR-T Cell Therapy
  • Tisagenlecleucel
  • Axicabtagene Ciloleucel
  • Future Perspective of CAR and CD19 CAR-T Cell Therapy
  • CAR Construct Delivery System
  • Novel CAR-T Models
  • CONCLUSION
  • CONSENT FOR PUBLICATION
  • CONFLICT OF INTEREST
  • ACKNOWLEDGEMENTS
  • REFERENCE
  • Dabrafenib in Melanoma
  • Meredith McKean and Rodabe N. Amaria*
  • INTRODUCTION
  • Mechanism of Action
  • Pharmacokinetics and Pharmacodynamics
  • Clinical Evaluations
  • Phase I and Phase II Studies
  • Phase III Studies
  • Dabrafenib for CNS Metastases
  • Dabrafenib/Trametinib Combination Therapy
  • Adjuvant Combination Targeted Therapy
  • Neoadjuvant Combination Targeted Therapy
  • Dabrafenib/Trametinib for CNS Metastases
  • Safety
  • Immunotherapy and Targeted Therapy
  • BRAF V600 Mutation in Other Malignancies
  • CONCLUSIONS
  • CONSENT FOR PUBLICATION
  • CONFLICT OF INTEREST
  • ACKNOWLEDGEMENTS
  • REFERENCES
  • Targeting Autophagy in Cancer Therapy
  • Maria Ines Vaccaro1,* and Claudio Daniel Gonzalez2
  • AUTOPHAGY IS AN EVOLUTIONARY HIGHLY PRESERVED PHYSIOLOGICAL PROCESS
  • Signaling Pathway for Autophagy
  • Autophagic Process
  • Functions of Autophagy
  • ALTERATIONS IN AUTOPHAGY ARE ASSOCIATED WITH TRANSITION FROM NORMAL TO NEOPLASTIC CELLS, AS WELL AS WITH CANCER CELL SURVIVAL AND RESISTANCE TO CHEMOTHERAPY
  • Autophagy in Normal to Neoplastic Cells
  • Autophagy in Cancer Cell Survival
  • Autophagy in Resistance to Chemotherapy
  • ACTIVATION AND INHIBITION OF AUTOPHAGY IN CHEMOTHERAPY OF CANCER
  • Cancer Cell Response After Autophagy Enhancement
  • Cancer Cell Response After Inhibition of Autophagy
  • AUTOPHAGY IN IMMUNOTHERAPY FOR CANCER
  • CONCLUSIONS AND PERSPECTIVES
  • CONSENT FOR PUBLICATION
  • CONFLICT OF INTEREST
  • ACKNOWLEDGEMENTS
  • REFERENCES
  • Selective Anti-Cancer Drugs against Multi-drug Resistance
  • Tijana Stankovic, Ana Podolski-Renic, Jelena Dinic and Milica Pesic*
  • INTRODUCTION
  • TARGETING ABC TRANSPORTERS' ACTIVITY
  • Verapamil Related Compounds
  • Niguldipine Analogs
  • Quinine Isomers
  • Cyclosporine A Derivatives
  • Synthetic Taxanes
  • Tetrahydroisoquinolin-ethyl-phenylamine Based Compounds
  • Quinoline Derivatives
  • Other Second-Generation Inhibitors
  • More Selective ABC Transporters' Inhibitors - Third-Generation
  • Multifunctional Drugs as Fourth-Generation Inhibitors
  • Peptidomimetics
  • Surfactants and Lipids
  • Dual Ligands
  • ROS PRODUCTION AND VULNERABILITY OF MDR CANCERS
  • ROS Production via Facilitation of ABC Transporters' ATPase
  • ROS Production via Iron Chelation
  • GLUTATHIONE DEPLETION
  • ENERGETIC ALTERATIONS
  • CHANGES IN PLASMA MEMBRANE
  • AUTOPHAGY MODULATION
  • MICROTUBULE COMPOSITION
  • OTHER EXAMPLES OF CS
  • NOVEL STRATEGIES FOR MDR TREATMENT
  • CONCLUDING REMARKS
  • CONSENT FOR PUBLICATION
  • CONFLICT OF INTEREST
  • ACKNOWLEDGEMENT
  • REFERENCES
  • Pro-Apoptotic and Anti-Telomerase Activity of Naturally Occurring Compounds
  • Mahendar Porika1,*, Radhika Tippani1 and Nazneen Firdous2
  • INTRODUCTION
  • Cancer
  • Telomerase
  • TELOMERASE COMPLEX AND ITS FORMATION
  • TELOMERASE AND CANCER
  • NON TELOMERIC ACTIVITIES OF TELOMERASE
  • TELOMERASE AND OXIDATIVE STRESS
  • TELOMERASE AND DNA DAMAGE/APOPTOSIS/DRUG RESISTANCE
  • NATURAL SOURCES AS ANTICANCER AGENTS
  • THE NEED FOR NATURISTIC ANTICANCER THERAPY
  • Plant Sources
  • Abnormal Savda Munzig
  • Apigenin
  • Berberine
  • Boldine
  • Butylidenephthalide
  • Crocin
  • Curcumin
  • (-) Epigallocatechin-3-Gallate
  • Gambogic Acid
  • Genistein
  • Helenalin
  • Indole- 3-carbinol
  • Papaverine
  • Pterostilbene
  • Quercetin
  • Resveratrol
  • Silymarin
  • Sulforaphane
  • Triptolide
  • Wogonin
  • CONCLUSION
  • CONSENT FOR PUBLICATION
  • CONFLICT OF INTEREST
  • ACKNOWLEDGEMENTS
  • REFERENCES
  • The Prospects of CDK Targeting and Clinical Application of CDK Inhibitors in Cancer
  • Aditi Gangopadhyay1,2,# and Aparna Gangopadhyay3,*, #
  • INTRODUCTION
  • REGULATION OF CDK ACTIVITY IS CRUCIAL FOR CELL CYCLE CONTROL
  • The Four Modes of CDK Regulation
  • Molecular Biology of Cyclin-Dependent Cell Cycle Regulation
  • Transition from G1 to S
  • Transition from S to G2
  • G2 to M Transition
  • DEREGULATION OF CDKS IN CANCERS
  • CDK TARGETING IN CANCER
  • Mechanism of CDK Inhibition
  • The Development of CDK Inhibitors
  • Inspired by Nature
  • Computer-Aided Drug Discovery (CADD)
  • THE CLINICAL DEVELOPMENT OF CDK INHIBITORS
  • The Evolution of Early Clinical Non-Selective CDK Inhibitors
  • First Generation CDK Inhibitors
  • Attempting to Improve Clinical Outcomes - Advent of Second Generation CDK Inhibitors
  • Selectivity is the Key
  • A Beacon in CDK Research: Selective Dual CDK 4/6 Inhibitors
  • Ushering in a New Age-Selective Dual CDK4/6 Inhibitors in the Clinic
  • Clinical Trials of Selective Dual CDK 4/6 Inhibitors in Breast Cancer
  • Palbociclib
  • Selective Dual CDK 4/6 Inhibitors in the Pipeline
  • Selective Dual CDK 4/6 Inhibitors in Other Cancers
  • Palbociclib
  • Ribociclib
  • Abemaciclib
  • Challenges in CDK Inhibitor Therapy
  • FUTURE SCOPE
  • CONSENT FOR PUBLICATION
  • CONFLICT OF INTEREST
  • ACKNOWLEDGEMENTS
  • REFERENCES
  • Advancements in Anticancer Drug Delivery
  • Hemant K.S. Yadav*, Abrar E. Srouji, Alyazya Mohammed and Manar Dibi
  • INTRODUCTION
  • HISTORY
  • NEW DRUGS FOR ANTICANCER THERAPY
  • Bavencio (Avelumab)
  • Nerlynx (Neratinib)
  • Zejula (Niraparib)
  • Xermelo (Telotristat Ethyl)
  • Imfinzi (Durvalumab)
  • Opdivo (Nivolumab)
  • dTCApFs
  • Apalutamide (Erleada)
  • Lutathera
  • Blinatumomab
  • DRUG-ANTIBODY CONJUGATES
  • CANCER DRUG DISCOVERY BY REPURPOSING
  • EXAMPLES OF REPURPOSED NON-CANCER DRUGS
  • Thalidomide
  • Aspirin
  • Metformin
  • COX-2 Inhibitors
  • Psychiatric Drugs
  • Statins
  • COMBINATION THERAPY IN COMBATING CANCER
  • Nivolumab and Ipilimumab Combination Therapy
  • Combination of Pharmaceutical Agents Targeting Antioxidant Response Pathways
  • Carbonic Anhydrase Inhibitors in Combination Therapy
  • Autocrine Growth Factors in Cancer Survival
  • Anti-Angiogenesis Therapeutic Agents in Combination Therapy
  • Histone Deacetylase Inhibitors in Combination Therapy
  • CONCLUSION
  • CONSENT FOR PUBLICATION
  • CONFLICT OF INTERESTS
  • ACKNOWLEDGEMENT
  • REFERENCES
  • Subject Index
  • Back Cover

Dateiformat: EPUB
Kopierschutz: Adobe-DRM (Digital Rights Management)

Systemvoraussetzungen:

Computer (Windows; MacOS X; Linux): Installieren Sie bereits vor dem Download die kostenlose Software Adobe Digital Editions (siehe E-Book Hilfe).

Tablet/Smartphone (Android; iOS): Installieren Sie bereits vor dem Download die kostenlose App Adobe Digital Editions (siehe E-Book Hilfe).

E-Book-Reader: Bookeen, Kobo, Pocketbook, Sony, Tolino u.v.a.m. (nicht Kindle)

Das Dateiformat EPUB ist sehr gut für Romane und Sachbücher geeignet - also für "fließenden" Text ohne komplexes Layout. Bei E-Readern oder Smartphones passt sich der Zeilen- und Seitenumbruch automatisch den kleinen Displays an. Mit Adobe-DRM wird hier ein "harter" Kopierschutz verwendet. Wenn die notwendigen Voraussetzungen nicht vorliegen, können Sie das E-Book leider nicht öffnen. Daher müssen Sie bereits vor dem Download Ihre Lese-Hardware vorbereiten.

Bitte beachten Sie bei der Verwendung der Lese-Software Adobe Digital Editions: wir empfehlen Ihnen unbedingt nach Installation der Lese-Software diese mit Ihrer persönlichen Adobe-ID zu autorisieren!

Weitere Informationen finden Sie in unserer E-Book Hilfe.


Download (sofort verfügbar)

89,50 €
inkl. 5% MwSt.
Download / Einzel-Lizenz
ePUB mit Adobe DRM
siehe Systemvoraussetzungen
E-Book bestellen